Merck Kgaa: (NA: MKGAF)

$160.00

0.00 (0.00%)

Volume NA

Jun 11 12:00 AM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		NA - NA
	
		52wk Low - High
		NA - NA
	
		Previous Close
		NA
	
		Avg. Volume
		5
	
		Industry
		MED-DRUGS
	
		Market Cap
		10.34 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.13
	
		P/E (F1)
		14.15
	
		Current Year Est.
		11.31
	
		Quarterly Earnings ESP 
		NA
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		No Zacks Recommendation
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		112 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of NA

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            14.15
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            11.31
                        
                            Current Quarter Estimate
                            NA
                        
                            Most Accurate Estimate
                            NA
                        
                            Earnings ESP 
                            NA
                        
                            Next Earnings Report Date
                            NA
                        
                            EPS Last Year
                            9.16
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Merck is a global pharmaceutical and chemical company. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.   
Full MKGAF Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
MKGAF Chart  by YCharts

Earnings Estimates

	Current Qtr (03/2013)	Next Qtr (06/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	NA	NA	11.31	12.43
Number of Estimates	0	0	1	1
Low Estimate	NA	NA	11.31	12.43
High Estimate	NA	NA	11.31	NA
Year Ago EPS	2.13	2.37	NA	11.31
EPS Growth	NA	NA	NA	9.90%

More MKGAF Estimates

Average Earnings Estimates for MKGAF

EPS Growth for MKGAF

Industry Analysis

Name	Symbol	Previous Close
MERCK KGAA	MKGAF	160.00
JAZZ PHARMACEUT	JAZZ	69.66
SALIX PHARM-LTD	SLXP	66.83
SANTARUS INC	SNTS	22.28
USANA HLTH SCI	USNA	74.58
ARADIGM CORP	ARDM	0.17
CELL THERAPEUT	CTIC	1.33
DURECT CORP	DRRX	0.83
ELAN CP PLC ADR	ELN	13.78
FLAMEL TECH	FLML	6.16

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Data on Merck KGaA's L-BLP25

May 22, 2013

Merck KGaA Posts Higher Y/Y Earnings

May 15, 2013

Merck KGaA-CBRX Renew Agreement

Apr 11, 2013

Sanofi Reports Lemtrada Data

Mar 27, 2013

Merck KGaA-BMY Collaborate

Mar 21, 2013

Merck KGaA - Nordic Bioscience Collaborate

Mar 20, 2013

Threshold Cuts Loss, Misses Sales

Mar 13, 2013

Strong Quarter for Merck KGaA

Mar 08, 2013

More MKGAF Zacks Commentary

Financials

EPS TTM	9.16
Sales	12,993
Net Income	554
Price/Earnings	17.47
Price/Book	0.78
Price/Cash Flow	3.09
Price/Sales	0.76

More MKGAF Financials

News

The Zacks Analyst Blog Highlights: Sanofi, Pfizer, Merck KGaA, Novartis and Biogen - Comtex

Sep 14, 2012

The Zacks Analyst Blog Highlights: Roche Holdings, Amgen, Merck KGaA, Eli Lilly and Bristol-Myers Squibb - Comtex

Jun 6, 2012

Zacks Analyst Blog Highlights: Merck KGaA, Teva Pharmaceuticals Industries, Biogen Idec, Elan and POSCO - Comtex

Nov 30, 2010

Merck KGaA and Millipore Announce Transaction - Video Interview with Merck CEO - Comtex

Mar 1, 2010

See All News Stories on MKGAF

Broker Recommendations

Current ABR	2.00
ABR (Last Week)	2.00
# of recs in ABR	2
Average Target Price	NA
Industry Rank by ABR	112 out of 265
Rank in Industry	17 out of 95

More MKGAF Broker Recommendations

Username: Password:

Remember me [?]

Forgot Password

New Member